MONTEREY, Calif. — Fewer adverse events overall were reported in eyes receiving Allergan’s Xen gel stent to treat glaucoma vs. eyes undergoing trabeculectomy at 12 months in the Gold Standard Pathway Study, according to a poster.
“As surgeons, anytime we consider surgery for a patient, we think about the implications of that surgery for the patient and the health of the eye,” Sahar Bedrood, MD, PhD, told Healio/OSN at the Women in Ophthalmology Summer Symposium, where she presented the data. “I ask myself, how will the patient recover from the (Read more...)